ClinicalTrials.gg
Active, not recruitingNCT03348631Updated Nov 18, 2026Results posted

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

A Phase 2 interventional study of Computed Tomography and Magnetic Resonance Imaging in Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm and Recurrent Ovarian Carcinoma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 581 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

Updated Oct 26, 2026Posted results revised5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 130 studies in Ovarian Neoplasms by National Cancer Institute (NCI) — 11 open to participants now, 37 under way, 5 of them phase 3. Ovarian Neoplasms · National Cancer Institute (NCI).

Enrollment
45th of 104
62 · median 52
Started
2019
with 2 others
Phase 2
50 of 130
4 open now
Primary completion
2023-07
later than 12 of 35 live
Registered
107th of 130
by date

Among the 130 studies in Ovarian Neoplasms by National Cancer Institute (NCI), this one is the 45th largest by enrollment of the 104 interventional ones that give a count, is one of 3 that started in 2019, is one of 50 in phase 2, reaches primary completion later than 12 of the 35 other live ones, and was the 107th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

11 of the 130 studies in Ovarian Neoplasms by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Ovarian Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the clinical activity (overall response rate) of tazemetostat in patients with recurrent or persistent endometrioid or clear cell ovarian carcinoma, and patients with recurrent or persistent endometrioid endometrial adenocarcinoma.

II. To assess the clinical activity (response frequency) of tazemetostat in patients with recurrent or persistent clear cell ovarian carcinoma with an ARID1A mutation.

SECONDARY OBJECTIVES:

I. To examine the nature and degree of toxicity in patients with this regimen. II. To examine the progression free survival and overall survival for this patient population receiving tazemetostat.

III. To examine the 6 month clinical benefit rate in patients treated with this regimen. (20-OCT-2021) IV. To evaluate BAF250a expression in patient samples as an indicator of ARID1A mutation status and correlation with the clinical response to study drug. Note: this only applies to patients enrolled prior to the 20-OCT-2021 version date. (20-OCT-2021)

EXPLORATORY OBJECTIVES:

I. Whether or not the patient has an ARID1A mutation. (08/13/2019) Note: this only applies to patients enrolled prior to the 20-OCT-2021 version date. (20-OCT-2021) (Translational Research Integrated Objective) II. To examine the correlation between ARID1A mutation and BAF250a expression and to identify potential mutations predictive of response in patients with preserved BAF250a expression. Note: this only applies to patients enrolled prior to the 20-OCT-2021 version date. (20-OCT-2021)

OUTLINE:

Patients receive tazemetostat orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scans and magnetic resonance imaging (MRI) on study.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

03

Conditions studied

  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • Recurrent Malignant Uterine Corpus Neoplasm
  • Recurrent Ovarian Carcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologically (histologically or cytologically) proven diagnosis of recurrent or persistent ovarian endometrioid or clear cell carcinoma, OR recurrent or persistent endometrioid endometrial adenocarcinoma; patients with recurrent endometrial cancer must have mismatch repair (MMR) immunohistochemistry completed; if they are found to be mismatch repair deficient, they should be offered treatment with immune checkpoint inhibition before consideration for treatment on trial; primary ovarian tumors must be at least 50% endometrioid or clear cell morphology, or have documented recurrence with at least 50% endometrioid or clear cell morphology; institutional pathology reports must be provided indicating at least 50% endometrioid or clear cell morphology for ovarian tumors (primary or recurrent lesions)

    • Only patients with recurrent or persistent ovarian clear cell carcinoma (OCCC) with ARID1A pathologic variant or likely pathologic variant mutations per next generation sequencing (NGS) are eligible for entry (20-OCT-2021)
    • Institutional pathology reports must be provided indicating at least 50% clear cell morphology for ovarian tumors (primary or recurrent lesions) and NGS report must be available for step 1 registration (20-OCT-2021) (09-DEC-2021)
    • All other eligibility criteria and ineligibility criteria must be met for step 2 registration (20-OCT-2021) (09-DEC-2021)
  • All patients must have as defined by (RECIST) version (v) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
  • Patients must have had at least one, but no more than 3, prior cytotoxic regimens for management of primary disease; unlimited prior hormonal therapy, targeted therapy (including immunotherapy) or antiangiogenic therapy will be permitted
  • Patients must have completed prior therapy:

    • Chemotherapy: cytotoxic

      • At least 28 days since last dose of chemotherapy prior to step 2 registration.
    • Chemotherapy: nitrosoureas

      • At least 6 weeks since last dose of chemotherapy prior to step 2 registration.
    • Chemotherapy: non-cytotoxic (e.g. small molecule inhibitor)

      • At least 28 days since last dose of chemotherapy prior to step 2 registration.
    • Monoclonal antibody(ies)

      • At least 28 days since last dose of monoclonal antibody prior to step 2 registration.
    • Immunotherapy

      • At least 28 days since last dose of immunotherapy prior to step 2 registration.
    • Radiotherapy (RT)

      • At least 14 days from last local site RT prior to step 2 registration.
      • At least 21 days from stereotactic radiosurgery prior to step 2 registration.
      • At least 12 weeks from craniospinal, >= 50% radiation of pelvis or total body irradiation prior to step 2 registration.
      • Patients with central nervous system (CNS) disease should demonstrate evidence of stabilization after the 28-day time point after definitive treatment.
      • Full recovery of radiation related side effects prior to step 2 registration.
      • All subjects must have evidence of measurable disease outside of the radiation field at the time of step 2 registration
  • Appropriate stage for study entry based on the following diagnostic workup:

    • History/physical examination within 14 days prior to step 2 registration
    • Imaging of the chest, abdomen and pelvis within 28 days prior to step 2 registration
  • Age >= 18
  • (ECOG) performance status of 0, 1 or 2 within 14 days prior to step 2 registration
  • >= 100,000/mcl (within 14 days prior to step 2 registration)
  • (ANC) >= 1,500/mcl (within 14 days prior to step 2 registration)
  • >= 8 g/dL (within 14 days prior to step 2 registration)
  • Differential with no morphologic abnormalities on complete blood count (CBC) testing; manual differential is encouraged, if clinically indicated, and in cases where an automated differential is abnormal (within 14 days prior to step 2 registration)
  • Creatinine =\< 1.5 x institutional/laboratory (ULN) (within 14 days prior to step 2 registration)
  • (AST) and alanine aminotransferase (ALT) =\< 3 x ULN (within 14 days prior to step 2 registration)
  • Total serum level =\< 1.5 x ULN; direct bilirubin =\< ULN for subjects with total bilirubin > 1.5 x ULN (patients with isolated indirect bilirubin elevations and a history of Gilbert's syndrome are eligible) (within 14 days prior to step 2 registration)
  • Patients must be able to swallow and retain oral medications and not have gastrointestinal illnesses that would preclude absorption of tazemetostat as judged by the treating physician (20-OCT-2021)
  • Women of must be willing and able to use adequate (hormonal and barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after the last dose of study agent; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately; theoretically, induction with tazemetostat use may result in the loss of efficacy in hormonal contraceptives, thus a barrier method of contraception must be used in addition to hormonal contraceptives due to the potential drug-drug interaction with tazemetostat (20-OCT-2021)
  • The patient or a legally authorized representative must provide study-specific and authorization permitting release of personal health information prior to study entry
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial (08/13/2019)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an EZH2 inhibitor
  • A prior history of myeloid , including myelodysplastic syndrome (MDS)
  • Abnormalities known to be associated with MDS (e.g. del 5q, chr 7 abn) and myeloproliferative neoplasms (MPN) (e.g. JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing
  • A prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL)
  • Patients who have had therapeutic paracentesis or thoracentesis within 8 weeks prior to step 2 registration (20-OCT-2021)
  • Patients with clinical or radiographic evidence of bowel obstruction (20-OCT-2021)
  • Severe, active co-morbidity per the treating investigator's discretion
  • Pregnant or lactating patients
  • Known (HIV) positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with tazemetostat; in addition, treatments involved in this protocol may be , increasing the risk of lethal infections in this patient population
  • Treatment with strong and moderate inhibitors or inducers of within 14 days of step 2 registration and during the study treatment (20-OCT-2021)
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Treatment (tazemetostat)

    Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans and MRI on study.

    Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Tazemetostat

Interventions

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given PO

    Also known as: E 7438, E-7438, E7438, EPZ 6438, EPZ-6438, EPZ6438

06

What researchers measure

Primary outcomes

  1. Tumor Response

    Will be defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. The statistic reported is the response rate (i.e. (total responses / total at risk) \* 100).

    Time frame: Up to 6 months

Secondary outcomes

  1. Tumor Response in Patients With ARID1A Mutations Using Tumor Response (Removed as of Version Date 20-OCT-2021)

    Will be defined by RECIST v 1.1.

    Time frame: Up to 6 months

  2. 6-month Progression Free Survival (Clinical Benefit Rate)

    Six-month progression free survival (clinical benefit rate). The clinical benefit rate is the total number (or percentage) of patients who had a complete response, or a partial response or who had stable disease for six months or more.

    Time frame: Up to 6 months

  3. Number of Patients With a Grade 3 (or Higher) Adverse Events

    Will be assessed according to grade of toxicity by organ or organ system. This will be reported by group (Endometrial or Ovarian). This study reported adverse events by CTCAE v5.0.

    Time frame: Adverse events were collected for a maximum of 23.5 months (interquartile range: 1.4 months, 3.9 months).

  4. Progression-free Survival

    Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.

    Time frame: Progression-free survival times were collected for a maximum of 30.0 months (interquartile range: 1.8 months, 5.5 months).

  5. Overall Survival

    Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.

    Time frame: Overall survival times were collected for a maximum of 51.6 months (interquartile range: 4.3 months, 19.0 months).

Other outcomes

  1. ARID1A Mutational Status

    ARID1A mutational status was ealuated by MSK-IMPACT.

    Time frame: Up to 6 months

  2. BAF250a Expression

    BAF250a expression was assessed by immunohistochemistry (IHC) as an indicator of ARID1A mutation status.

    Time frame: Up to 6 months

07

Results

Posted Mar 6, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
Started1943
Completed1642
Not completed31
Withdrew: Not eligible, no treatment01
Withdrew: Not eligible, treated20
Withdrew: Eligible, no treatment10

Outcome measures

PrimaryTumor Response

Will be defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. The statistic reported is the response rate (i.e. (total responses / total at risk) \* 100).

Time frame:
Up to 6 months
Reported as:
Number · Response/Patient (Percentage)
Tumor Response
Response/Patient (Percentage)Arm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
Tumor Response0 (0 to 15)4.7 (0.6 to 15.8)
SecondaryTumor Response in Patients With ARID1A Mutations Using Tumor Response (Removed as of Version Date 20-OCT-2021)

Will be defined by RECIST v 1.1.

Time frame:
Up to 6 months

Results for this outcome have not been posted.

Secondary6-month Progression Free Survival (Clinical Benefit Rate)

Six-month progression free survival (clinical benefit rate). The clinical benefit rate is the total number (or percentage) of patients who had a complete response, or a partial response or who had stable disease for six months or more.

Time frame:
Up to 6 months
Reported as:
Number · Percentage with 6-month PFS
6-month Progression Free Survival (Clinical Benefit Rate)
Percentage with 6-month PFSArm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
6-month Progression Free Survival (Clinical Benefit Rate)25 (7.3 to 52.4)19 (8.6 to 34.1)
SecondaryNumber of Patients With a Grade 3 (or Higher) Adverse Events

Will be assessed according to grade of toxicity by organ or organ system. This will be reported by group (Endometrial or Ovarian). This study reported adverse events by CTCAE v5.0.

Time frame:
Adverse events were collected for a maximum of 23.5 months (interquartile range: 1.4 months, 3.9 months).
Reported as:
Count of participants · Participants
Number of Patients With a Grade 3 (or Higher) Adverse Events
ParticipantsArm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
Number of Patients With a Grade 3 (or Higher) Adverse Events620
SecondaryProgression-free Survival

Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.

Time frame:
Progression-free survival times were collected for a maximum of 30.0 months (interquartile range: 1.8 months, 5.5 months).
Reported as:
Median · months
Progression-free Survival
monthsArm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
Progression-free Survival2.05 (1.84 to 5.49)3.04 (2.04 to 4.37)
SecondaryOverall Survival

Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.

Time frame:
Overall survival times were collected for a maximum of 51.6 months (interquartile range: 4.3 months, 19.0 months).
Reported as:
Median · months
Overall Survival
monthsArm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
Overall Survival25.3 (3.8 to NA)13.7 (8.0 to 22.4)
Other pre-specifiedARID1A Mutational Status

ARID1A mutational status was ealuated by MSK-IMPACT.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
ARID1A Mutational Status
ParticipantsArm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
ARID1A Mutational Status69
Other pre-specifiedBAF250a Expression

BAF250a expression was assessed by immunohistochemistry (IHC) as an indicator of ARID1A mutation status.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
BAF250a Expression
ParticipantsArm I: Treatment (Tazemetostat) in Endometrial CancerArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
BAF250a Expression1212

Adverse events

Collected over Adverse events were collected for a maximum of 23.5 months (interquartile range: 1.4 months, 3.9 months). All-Cause Mortality monitored/assessed up to 51.6 months (interquartile range: 4.3 months, 19.0 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients11/16 (68.8%)3/16 (18.8%)15/16 (93.8%)
Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients28/42 (66.7%)12/42 (28.6%)40/42 (95.2%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventArm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
NauseaGastrointestinal disorders2/163/42
Abdominal painGastrointestinal disorders1/162/42
Colonic obstructionGastrointestinal disorders1/160/42
VomitingGastrointestinal disorders1/160/42
Disease progressionGeneral disorders1/162/42
FatigueGeneral disorders1/160/42
ArthralgiaMusculoskeletal and connective tissue disorders1/160/42
MyalgiaMusculoskeletal and connective tissue disorders1/160/42
AtaxiaNervous system disorders1/160/42
ParesthesiaNervous system disorders1/160/42
Most frequent other events
Showing 10 of 133
Most frequent other events
EventArm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer Patients
NauseaGastrointestinal disorders6/1623/42
FatigueGeneral disorders7/1620/42
AnemiaBlood and lymphatic system disorders7/1616/42
DiarrheaGastrointestinal disorders6/169/42
Abdominal painGastrointestinal disorders5/169/42
VomitingGastrointestinal disorders3/1613/42
AnorexiaMetabolism and nutrition disorders3/1612/42
DyspneaRespiratory, thoracic and mediastinal disorders1/1611/42
DysgeusiaNervous system disorders4/166/42
HeadacheNervous system disorders4/164/42

Baseline characteristics

All enrolled patients

Age, Customized
Age, Customized(Participants)Arm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer PatientsTotal
20-29 years011
30-39 years011
40-49 years066
50-59 years51621
60-69 years111627
70-79 years134
>= 80 years202
Sex: Female, Male
Sex: Female, Male(Participants)Arm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer PatientsTotal
Female194362
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer PatientsTotal
Hispanic or Latino022
Not Hispanic or Latino194059
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I: Treatment (Tazemetostat) in Endometrial Cancer PatientsArm II: Treatment (Tazemetostat) Ovarian in Cancer PatientsTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American325
White163753
More than one race000
Unknown or Not Reported022
08

Study locations

581 sites

Showing the first 100 of 581 sites. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Data sharing details ↗ · grants.nih.gov

10

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jul 2023, 50 months.

Results were first posted in Mar 2025, 1 year 7 months after primary completion.

Of 228 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's 50 months is close to that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Nov 21, 2017
StartActual
May 1, 2019
Primary completionActual
Jul 28, 2023
CompletionEst.
Feb 12, 2027
Results first posted
Mar 6, 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Sep 29, 2026
Sites
5 sites added, 6 sites removed
Show 5 added (5 United States)
  • CommonSpirit Saint Joseph Hospital - Bardstown · Bardstown, United States
  • CommonSpirit Saint Joseph Medical Center - East Lexington · Lexington, United States
  • CommonSpirit Saint Joseph Hospital London · London, United States
  • Saint Anne Hospital · Burien, United States
  • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
Show 6 removed
  • Flaget Memorial Hospital · Bardstown, United States
  • Saint Joseph Hospital East · Lexington, United States
  • Saint Joseph London · London, United States
  • BJC Outpatient Center at Sunset Hills · Sunset Hills, United States
  • Highline Medical Center-Main Campus · Burien, United States
  • Newland Medical Associates-Pontiac · Pontiac, United States
across 4 updates, Sep 29, 2026 – Oct 26, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • Descriptionother outcomeARID1A Mutational Status: how it is measured was reworded
  • Descriptionother outcomeBAF250a Expression: how it is measured was reworded
Sep 29, 2026
Show all 6 updates
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: responsible party
  2. Nov 13, 2026
    Minor edits only
    + 1 other change: responsible party
  3. Oct 26, 2026
    1 site added, 1 site removed
    Show site
    • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
    Show 1 removed
    • Newland Medical Associates-Pontiac · Pontiac, United States
  4. Oct 22, 2026
    1 site added, 1 site removed
    Show site
    • Saint Anne Hospital · Burien, United States
    Show 1 removed
    • Highline Medical Center-Main Campus · Burien, United States
  5. Sep 30, 2026
    1 site removed
    Show 1 removed
    • BJC Outpatient Center at Sunset Hills · Sunset Hills, United States
    + 1 other change: verification date
  6. Sep 29, 2026
    Posted results revised
    3 sites added, 3 sites removed
    Show 3 added (3 United States)
    • CommonSpirit Saint Joseph Hospital - Bardstown · Bardstown, United States
    • CommonSpirit Saint Joseph Medical Center - East Lexington · Lexington, United States
    • CommonSpirit Saint Joseph Hospital London · London, United States
    Show 3 removed
    • Flaget Memorial Hospital · Bardstown, United States
    • Saint Joseph Hospital East · Lexington, United States
    • Saint Joseph London · London, United States
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • Descriptionother outcomeARID1A Mutational Status: how it is measured was reworded
    • Descriptionother outcomeBAF250a Expression: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03348631
Collaborators
NRG Oncology
Responsible party
Sponsor
First posted
Nov 21, 2017
Start date
May 1, 2019
Primary completion
Jul 28, 2023
Completion
Feb 12, 2027 (estimated)
Results posted
Mar 6, 2025
Last update
Nov 18, 2026

Study contacts

Ramez N Eskander
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tazemetostat

Start the discussion